Novo Nordisk A/S (NVO) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $42.47 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk).
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides... Read more
Sell if holding. Analyst target reached at $42.47 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 71. Score 5.3/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $42.47 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $39.75. Score 5.3/10, moderate confidence.
Take-profit target: $41.99 (-1.1% upside). Prior stop was $39.75. Stop-loss: $39.75.
Analyst target reached - limited upside remaining; Earnings in 6 days (event risk); Earnings estimates trending DOWN.
Novo Nordisk A/S trades at a P/E of 11.2 (forward 11.7). TrendMatrix value score: 7.0/10. Verdict: Sell.
37 analysts cover NVO with a consensus score of 3.4/5. Average price target: $46.
What does Novo Nordisk A/S do?Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.